Does the Ethnic Difference Affect the Pharmacokinetics of Favipiravir? A Pharmacokinetic Study in Healthy Egyptian Volunteers and Development of Level C In-vitro In-vivo Correlation
Drug Res (Stuttg) DOI: 10.1055/a-2061-7074Favipiravir is an antiviral drug used to treat influenza and is also being
investigated for the treatment of SARS-CoV-2. Its pharmacokinetic profile varies
depending on ethnic group. The present research examines the pharmacokinetic
features of favipiravir in healthy male Egyptian volunteers. Another goal of
this research is to determine the optimum dissolution testing conditions for
immediate release tablets. In vitro dissolution testing was investigated for
favipiravir tablets in three different pH media. The pharmacokinetic features of
favipiravir were examined in 27 healthy male Egyptian volunteers. The parameter
“AUC0-t” vs. percent dissolved was used to develop level C in
vitro in vivo correlation (IVIVC) to set the optimum dissolution medium to
achieve accurate dissolution profile for favipiravir (IR) tablets. The in vitro
release results revealed significant difference among the three different
dissolution media. The Pk parameters of twenty-seven human subjects showed mean
value of Cpmax of 5966.45 ng/mL at median tmax of 0.75 h
with AUC0-∞ equals 13325.54 ng.h/mL, showing half-life
of 1.25 h. Level C IVIVC was developed successfully. It was concluded
that Egyptian volunteers had comparable Pk values to American and Caucasian
volunteers, however ...
Source: Drug Research - Category: Drugs & Pharmacology Authors: Bendas, Ehab R. Rezk, Mamdouh R. Badr, Kamal A. Tags: Original Article Source Type: research